Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL11743887 | 0.85 | TSHR (0.37) | ACHEALDH1A1TAAR1CYP3A4HSD17B10 | |
| Bromide SCHEMBL5092862 | 0.85 | TSHR (0.37) | ACHEALDH1A1TAAR1CYP3A4HSD17B10 | |
| Fluoride Ion SCHEMBL2467473 | 0.85 | TSHR (0.37) | ACHEALDH1A1TAAR1CYP3A4HSD17B10 | |
| Iodide SCHEMBL5091418 | 0.85 | TSHR (0.37) | ACHEALDH1A1TAAR1CYP3A4HSD17B10 | |
| Hydrochloric Acid SCHEMBL2468397 | 0.85 | TSHR (0.37) | ACHEALDH1A1TAAR1CYP3A4HSD17B10 | |
| SCHEMBL11022349 | 0.79 | — | — | |
| SCHEMBL11019139 | 0.79 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL7892826 | 0.77 | ALDH1A1 (0.39) | ACHEALDH1A1CYP3A4HSD17B10TDP1 | |
| SCHEMBL11023417 | 0.72 | TP53 (0.35) | ACHEALDH1A1HSD17B10LMNA | |
| Biphenyl SCHEMBL17388552 | 0.68 | ALDH1A1 (0.75) | ACHEALDH1A1TAAR1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005524748-A | — | — | 2005-08-18 | — | — | JP | claimed |
| US-6852417-B2 | Composition for improving adhesion of base-resistant fluoroelastomers to metal, ceramic or glass substrates | DUPONT DOW ELASTOMERS, LLC (US) | 2005-02-08 | — | — | US | claimed |
| EP-1501887-A1 | COMPOSITION FOR IMPROVING ADHESION OF BASE-RESISTANT FLUOROELASTOMERS TO METAL, CERAMIC OR GLASS SUBSTRATES | DUPONT DOW ELASTOMERS L.L.C. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20030225189-A1 | Composition for improving adhesion of base-resistant fluoroelastomers to metal, ceramic or glass substrates | DUPONT DOW ELASTOMERS LLC | 2003-12-04 | — | — | US | claimed |
| WO-2003095535-A1 | COMPOSITION FOR IMPROVING ADHESION OF BASE-RESISTANT FLUOROELASTOMERS TO METAL, CERAMIC OR GLASS SUBSTRATES | DUPONT DOW ELASTOMERS L.L.C. (US) | 2003-11-20 | — | — | WO | claimed |
| US-20260098005-A1 | NON-FLUORINATED RESORCINOL AND HYDROQUINONE ANALOGS AS CURING AGENTS FOR FLUOROELASTOMERS | THE CHEMOURS COMPANY FC, LLC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4602105-A1 | CURABLE FLUOROELASTOMER COMPOSITIONS AND LOW-FRICTION CURED FLUOROELASTOMERS (FKM) FORMED THEREFROM | The Chemours Company FC, LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4590761-A1 | NON-FLUORINATED RESORCINOL AND HYDROQUINONE ANALOGS AS CURING AGENTS FOR FLUOROELASTOMERS | The Chemours Company FC, LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4590762-A1 | FLUORINATED RESORCINOL AND HYDROQUINONE ANALOGS AS CURING AGENTS FOR FLUOROELASTOMERS | The Chemours Company FC, LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-120092046-A | Curable fluoroelastomer compositions and low friction cured fluoroelastomers (fkM) formed therefrom | 科慕埃弗西有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119998379-A | Non-fluorinated resorcinol and hydroquinone analogs as curing agents for fluoroelastomers | 科慕埃弗西有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240239931-A1 | FLUORINATED RESORCINOL AND HYDROQUINONE ANALOGS AS CURING AGENTS FOR FLUOROELASTOMERS | CHEMOURS COMPANY FC, LLC, THE | 2024-07-18 | — | — | US | disclosed |
| US-20030065132-A1 | Curable base-resistant fluoroelastomers | THE CHEMOURS COMPANY FC, LLC | 2003-04-03 | — | — | US | disclosed |
| US-20030004277-A1 | Curable base-resistant fluoroelastomers | THE CHEMOURS COMPANY FC, LLC | 2003-01-02 | — | — | US | disclosed |
| WO-2002092683-A1 | CURABLE BASE-RESISTANT FLUOROELASTOMERS | DUPONT DOW ELASTOMERS L.L.C. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092687-A1 | CURABLE BASE-RESISTANT FLUOROELASTOMERS | DUPONT DOW ELASTOMERS L.L.C. (US) | 2002-11-21 | — | — | WO | disclosed |
| US-6221971-B1 | MIXTURE CONTAINING A BASE | DUPONT DOW ELASTOMERS, L.L.C. | 2001-04-24 | — | — | US | disclosed |
| US-6020440-A | SALT FORMATION; MIXING WITH ACID ACCEPTOR; CROSSLINKING | DUPONT DOW ELASTOMERS, L.L.C. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0905177-A1 | Process for curing elastomeric vinylidene fluoride copolymers | DUPONT DOW ELASTOMERS L.L.C. (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0161128-A1 | Two-component dry electrostatic developer composition | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098005-A1 | NON-FLUORINATED RESORCINOL AND HYDROQUINONE ANALOGS AS CURING AGENTS FOR FLUOROELASTOMERS | CBR1, NAF1, CBR3 | ACHE 3378/4885ALDH1A1 428/4885TAAR1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.